Geographic Atrophy Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | Apellis Pharmaceuticals, Iveric Bio (formerly Ophthotech Corporation), Alkeus Pharmaceuticals, Hemera Biosciences, Allegro Ophthalmic

DelveInsight's "Geographic Atrophy Market Insights, Epidemiology, and Market Forecast- 2034" report delivers an in-depth understanding of the Geographic Atrophy, historical and forecasted epidemiology as well as the Geographic Atrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover which therapies are expected to grab the Geographic Atrophy Market Share @ Geographic Atrophy Market Outlook- https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Geographic Atrophy Market Report
• In April 2025, Boehringer Ingelheim announced a study is open to adults aged 55 years and older with geographic atrophy that was diagnosed by imaging of the retina. The purpose of this study is to find out whether a medicine called BI 1584862 improves the eyes in people with geographic atrophy and to find the most suitable dose.
• In April 2025, Janssen Research & Development LLC conducted a phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD).
• In April 2025, Hoffmann-La Roche conducted a study is evaluation of the safety and tolerability of OpRegen - Human embryonic stem cell-derived retinal pigment epithelial (RPE) cells. The study will also include initial exploration of the ability of transplanted OpRegen cells to engraft, survive, and moderate disease progression.
• In February 2025, Astellas Pharma announced that the FDA approved expanded prescribing information for IZERVAYTM (avacincaptad pegol intravitreal solution) for treating geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The approval removes the limitation on the duration of dosing, offering physicians and patients more flexibility in managing GA.
• The total prevalent cases of AMD in the 7MM was nearly 68,347,900 in 2023.
• Among the 7MM, the US accounted for the highest prevalent cases of Geographic Atrophy in 2023 while Japan accounted for the least number of prevalent cases.
• Amongst EU4 and the UK, the highest number of cases comprised from France and Germany, with France having slightly more cases than Germany.
• In 2023, the geographical atrophy accounted for nearly 955,900 cases in EU4 and the UK.
• According to the estimates, in Japan, it is observed that age-specific cases of Geographic Atrophy were most prevalent in the 85+ years age group, accounting for over 40% of total cases in 2023.
• Although there are relatively equal numbers of neovascular AMD and Geographic Atrophy in White populations, late AMD is less common among Japanese people than among white subjects. In Asian countries, although the prevalence of Geographic Atrophy is low, the rapidly aging population means that Geographic Atrophy is becoming an increasingly urgent and unmet medical need. The difference in the prevalence of AMD among races is also partly owing to genetic background; for example, some single nucleotide polymorphisms (SNPs) in complement factors are associated with AMD in Caucasians.
• The increase in Geographic Atrophy Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Geographic Atrophy Market is anticipated to witness growth at a considerable CAGR.
• The leading Geographic Atrophy Companies such as Apellis Pharmaceuticals, Iveric Bio (formerly Ophthotech Corporation), Alkeus Pharmaceuticals, Hemera Biosciences, Allegro Ophthalmics, Stealth BioTherapeutics, Regenerative Patch Technologies, Novartis, Roche, Ionis Pharmaceuticals, CellCure Neurosciences, and others.
• Promising Geographic Atrophy Pipeline Therapies such as OCU410, Danicopan, BI 1584862, Tinlarebant, OpRegen, ANX007, NGM621, and others.

Stay ahead in the Geographic Atrophy Therapeutics Market with DelveInsight's Strategic Report @ Geographic Atrophy Market Outlook- https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Geographic Atrophy Epidemiology Segmentation in the 7MM
The epidemiology section of Geographic Atrophy offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.
• Total Prevalent Cases of AMD in the 7MM
• Late Stage-specific Prevalent Cases of AMD in the 7MM
• Total Prevalent Cases of Geographic Atrophy in the 7MM
• Total Diagnosed Prevalent Cases of Geographic Atrophy in the 7MM
• Age-specific Cases of Geographic Atrophy in the 7MM
• Geographic Atrophy Cases by Visual Impairment in the 7MM

Download the report to understand which factors are driving Geographic Atrophy Epidemiology Trends @ Geographic Atrophy Prevalence- https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Marketed Geographic Atrophy Drugs
• IZERVAY (avacincaptad pegol): Astellas Pharma/Iveric Bio
IZERVAY, also known as avacincaptad pegol is designed to target and inhibit complement factor C5. Complement factor C5 is a central component of the complement cascade and is believed to be involved in the development and progression of dry AMD. IZERVAY binds to C5 and inhibits its cleavage into the terminal fragments C5a and C5b. By inhibiting the formation of complement system terminal fragments, IZERVAY may decrease the activation of inflammasomes and the formation of membrane attack complexes (MAC), which occur at the end of the complement cascade. In August 2023, the US FDA approved IZERVAY for the treatment of Geographic Atrophy secondary to AMD. Concurrently, Astellas Pharma announced that the European Medicines Agency (EMA) has accepted Iveric Bio's MAA for avacincaptad pegol for the treatment of Geographic Atrophy secondary to AMD.

• SYFOVRE (pegcetacoplan): Apellis Pharmaceuticals
SYFOVRE is a targeted C3 inhibitor designed to regulate excessive complement activation, which can lead to the onset and progression of many serious diseases. Pegcetacoplan is a type of synthetic cyclic peptide conjugated to a polyethylene glycol polymer that binds specifically to C3 and C3b. The company is evaluating pegcetacoplan in several clinical studies, including paroxysmal nocturnal hemoglobinuria (PNH), Geographic Atrophy (GA), cold agglutinin disease (CAD), warm antibody autoimmune hemolytic anemia (wAIHA), complement-dependent nephropathies (CDN). SYFOVRE is the first and only approved therapy for Geographic Atrophy secondary to AMD. In January 2024, the CHMP of the EMA adopted a negative opinion on the MAA of intravitreal pegcetacoplan for the treatment of Geographic Atrophy secondary to AMD

Emerging Geographic Atrophy Drugs
• Tinlarebant (LBS-008): Belite Bio
Tinlarebant is a novel oral therapy that is intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to GA, or advanced dry AMD. These toxins are by-products of the visual cycle, which is dependent on the supply of vitamin A (retinol) to the eye. A 2-year global Phase III PHOENIX trial is ongoing. PHOENIX is a multicenter, randomized, double-masked, placebo-controlled study to evaluate the safety and efficacy of Tinlarebant in Geographic Atrophy subjects. In November 2023, Belite Bio announced the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom (UK) for the Phase III clinical trial of Tinlarebant in Geographic Atrophy or the PHOENIX study.

• Gildeuretinol (ALK-001): Alkeus Pharmaceuticals
Allegro Ophthalmics is developing risuteganib (also known as ALG-1001), a breakthrough integrin-regulating therapy for ocular health that reduces mitochondrial dysfunction involved in intermediate dry AMD. By targeting multiple pathways, risuteganib helps reduce the cellular burden of oxidative stress and restores retinal homeostasis. Research suggests that risuteganib interferes with integrin functions that have been implicated in retinal diseases, giving it the potential for a broad-spectrum effect on different pathways of oxidative stress. Currently, the company has received the US FDA agreement under Special Protocol Assessment (SPA) for Phase IIb/III clinical trial of risuteganib for the treatment of intermediate, non-exudative age-related macular degeneration (dry AMD). Moreover, the overall protocol design of Phase IIb/III dry AMD clinical trial was finalized by the US FDA. According to the company's recent presentation, a Phase III study of gildeuretinol in 200 patients with Geographic Atrophy secondary to AMD has recently been completed and is expected to read out topline data in 2024.

To learn more about Geographic Atrophy treatment guidelines, visit @ Geographic Atrophy Treatment Market Landscape- https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Geographic Atrophy Market Outlook
Geographic Atrophy, the advanced stage of dry AMD, has emerged as a prominent focus of research. Current investigations predominantly center on therapies targeting complement inhibitors of C3 and C5, pivotal factors in triggering inflammation and subsequent cell death within the eye. Extensive studies led by the National Eye Institute and esteemed researchers globally have unveiled the likelihood of an overactive complement system as a central player in the genesis of dry AMD and its evolution toward Geographic Atrophy.

Geographic Atrophy Drugs Uptake
The drug chapter of the Geographic Atrophy report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Geographic Atrophy.

Major Geographic Atrophy Companies
Apellis Pharmaceuticals, Iveric Bio (formerly Ophthotech Corporation), Alkeus Pharmaceuticals, Hemera Biosciences, Allegro Ophthalmics, Stealth BioTherapeutics, Regenerative Patch Technologies, Novartis, Roche, Ionis Pharmaceuticals, CellCure Neurosciences, and others

Learn more about the FDA-approved drugs for Geographic Atrophy @ Drugs for Geographic Atrophy Treatment- https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Geographic Atrophy Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Geographic Atrophy Companies-Apellis Pharmaceuticals, Iveric Bio (formerly Ophthotech Corporation), Alkeus Pharmaceuticals, Hemera Biosciences, Allegro Ophthalmics, Stealth BioTherapeutics, Regenerative Patch Technologies, Novartis, Roche, Ionis Pharmaceuticals, CellCure Neurosciences, and others.
• Geographic Atrophy Pipeline Therapies- OCU410, Danicopan, BI 1584862, Tinlarebant, OpRegen, ANX007, NGM621, and others.
• Geographic Atrophy Market Dynamics: Geographic Atrophy Market Drivers and Barriers
• Geographic Atrophy Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Geographic Atrophy Drugs in development @ Geographic Atrophy Clinical Trials Assessment- https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Geographic Atrophy Executive Summary
3. Geographic Atrophy Competitive Intelligence Analysis
4. Geographic Atrophy: Market Overview at a Glance
5. Geographic Atrophy: Disease Background and Overview
6. Patient Journey
7. Geographic Atrophy Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Geographic Atrophy Unmet Needs
10. Key Endpoints of Geographic Atrophy Treatment
11. Geographic Atrophy Marketed Products
12. Geographic Atrophy Emerging Therapies
13. Geographic Atrophy: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Geographic Atrophy Market Outlook
16. Access and Reimbursement Overview of Geographic Atrophy
17. KOL Views
18. Geographic Atrophy Market Drivers
19. Geographic Atrophy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

List of Top Selling Market Research Reports in 2025

NK Cell Therapy Market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Novel Drug Delivery Devices Market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Psoriasis Vulgaris Market- https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
Surgical Energy Instruments Market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Urea Cycle Disorders Market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
Immune Checkpoints Activators Market- https://www.delveinsight.com/report-store/immune-checkpoint-inhibitors-market
Vitreoretinal Surgery Devices Market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
Cystic Fibrosis Market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Surgical Robotic System Market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/neurovascular-thrombectomy-devices-market
Diabetic Wound Market- https://www.delveinsight.com/report-store/diabetic-wounds-market
Indwelling Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market
Attention Deficit Hyperactivity Disorder Market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Overactive Bladder Syndrome Market- https://www.delveinsight.com/report-store/underactive-bladder-market
Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market
Healthcare Competitive Benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Thyroid Cancer Market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Intraocular Lens Market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
Cardiac Monitoring Devices Market- https://www.delveinsight.com/blog/cardiac-monitoring-devices-market
Antibody Drug Conjugate Market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Surgical Mask & Respirator Market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Total Knee Arthroplasty Market - https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Bone Growth Stimulator Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.